Abstract
Oncology drug development has been increasingly shaped by molecularly targeted agents (MTAs), which often demonstrate differential effectiveness driven by the biomarker expression levels on tumors. Innovative statistical designs have been proposed to tackle this challenge, e.g., Freidlin et al. [3, 4], Jiang et al. [7]. All of these are essentially adaptive confirmatory Phase 3 designs that combine the testing of treatment effectiveness in the overall population with an alternative pathway for a more restrictive efficacy claim in a sensitive subpopulation. We believe that, in cases that there are strong biological rationales to support that a MTA may provide differential benefit in a general patient population; proof-of-concept (POC) is likely intertwined with predictive enrichment. Therefore, it is imperative that early phase POC studies be designed to specifically address biomarker-related questions to improve the efficiency of development. In this paper, we propose three strategies for detecting efficacy signals in single-arm studies that allow claiming statistical significance either in the overall population or in a biomarker enriched subpopulation. None of the three methods requires pre-specification of biomarker thresholds, but still maintains statistical rigor in the presence of multiplicity. The performance of these proposed methods are evaluated with simulation studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alosh, M., Huque, M.F.: A flexible strategy for testing subgroups and overall population. Stat. Med. 28, 3–23 (2009)
Alosh, M., Huque, M.F.: A consistency-adjusted alpha-adaptive strategy for sequential testing. Stat. Med. 29, 1559–1571 (2010)
Freidlin, B., Simon, R.: Adaptive signature design: an adaptive clinical trial design for generating 1519 and prospectively testing a gene expression signature for sensitive patients. Clin. Cancer 1520 Res. 11, 7872–7878 (2005)
Freidlin, B, Jiang, W., Simon, R.: The cross-validated adaptive signature design. Clin. Cancer 1522 Res. 16, 691–698 (2010)
Food and Drug Administration. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products, 25 May 2005
Hall, P., Wilson, S.: Two guidelines for bootstrap hypothesis testing. Biometrics 47(2), 757–762 (1991)
Jiang, W., Freidlin, B., Simon, R.: Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J. Natl. Cancer Inst. 99(13), 1036–1043 (2007)
Lyles, R., Lin, J.: Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting. Stat. Med. 29(22), 2297–2309 (2010)
Song, Y., Chi, G.Y.: A method for testing a prespecified subgroup in clinical trials. Stat. Med. 26, 3535–3549 (2007)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this paper
Cite this paper
Tian, H., Liu, K. (2019). Biomarker Enrichment Design Considerations in Oncology Single Arm Studies. In: Liu, R., Tsong, Y. (eds) Pharmaceutical Statistics. MBSW 2016. Springer Proceedings in Mathematics & Statistics, vol 218. Springer, Cham. https://doi.org/10.1007/978-3-319-67386-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-67386-8_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67385-1
Online ISBN: 978-3-319-67386-8
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)